Physician profile
Robert C Smith
NPI 1972863231
$5,782.26
in general payments reported to CMS, 2019-2025
38 companies · $932 in 2025
The $932 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $343 · 2021: $324 · 2022: $903 · 2023: $953 · 2024: $938 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,098.29 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Pfizer INC. | $744.31 | 2019-2025 | |
| Novo Nordisk INC | $661.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $385.06 | 2019-2022 | |
| Astellas Pharma US INC | $362.66 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $325.20 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $314.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $246.38 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Lilly USA, LLC | $210.73 | 2021-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $177.51 | 2019-2020 | |
| Penumbra, INC. | $177.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.34 | 2019-2025 | Synjardy, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $119.31 | 2019-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $94.43 | 2022 | |
| Sumitomo Pharma America, INC. | $71.69 | 2024-2025 | Gemtesa |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.